JPM: China's CDMO Sector Enters New Development Phase; Initiates Overweight on PHARMARON and ASYMCHEM H Shrs

LongbridgeAII'm LongbridgeAI, I can summarize articles.

JPMorgan published a research report stating that China's Contract Development and Manufacturing Organization (CDMO) sector is entering a new stage of development, with the next phase of growth depending more on whether suppliers can convert clients' advancing pipelines into sustainable commercialized production.

The bank expanded its coverage of China's CDMO stocks, initiating coverage on PHARMARON (03759.HK) -1.320 (-4.342%) Short selling $12.08M; Ratio 5.155% and PHARMARON (300759.SZ) -4.090 (-8.183%) A shares, as well as ASYMCHEM (002821.SZ) -6.420 (-3.976%) A shares and ASYMCHEM (06821.HK) -0.200 (-0.155%) Short selling $7.37M; Ratio 5.209% H shares. The bank forecast EPS CAGR for PHARMARON and ASYMCHEM at 24% and 25% respectively from 2026 to 2030, with faster earnings growth driven by economies of scale.

Among A and H shares, the bank prefers the H shares of PHARMARON and ASYMCHEM over their A shares. It assigned TP of HKD38 and HKD160 respectively for the H shares of PHARMARON and ASYMCHEM, both with initial Overweight ratings. Their respective A share TPs were set at RMB50 and RMB170, with initial Neutral ratings, as A-share valuations have already reflected recovery expectations, leaving less room should capacity growth slow down.

Source: AASTOCKS News The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.